Real-World study tracks darolutamide use in advanced prostate cancer
NCT ID NCT07406282
First seen Jun 27, 2026 · Last updated Jul 08, 2026 · Updated 2 times
Summary
This study is not testing a new drug but rather observing how darolutamide is actually used in everyday urology clinics for men with metastatic hormone-sensitive prostate cancer. Researchers will review medical records of about 1,400 patients to understand who gets which treatment combinations and how they fare. The goal is to fill knowledge gaps and help doctors make better treatment decisions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Precision Point Specialty LLC PPS Analytics, a Specialty Networks LLC Company
RECRUITINGCleveland, Ohio, 44114-2619, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Half the dose, same hope? trial tests cutting hormone therapy in prostate cancer
- Can a smart drug deliver a toxic payload to prostate cancer cells?
- Can AI outthink cancer experts? a landmark trial pits five AIs against tumor boards
- Hormone therapy showdown: can an oral pill beat the shot for prostate cancer patients?
- Can a new daily pill slow advanced prostate cancer?
- Immunotherapy combo takes on Hard-to-Treat prostate cancer